Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded ...

Regeneron Pharmaceuticals, Inc. announced that it will present new and updated data from its oncology and hematology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced financial results for the first quarter of 2025 and provided a business update. "We have ...

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago.The ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS (a) of $8.22 First quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 19% to $ ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS (a) of $8.22; First quarter 2025 Dupixent ® global net sales (recorded by Sanofi) ...

The foods you eat can be one of the most significant contributors to high cholesterol. Generally, foods high in saturated fat (considered an unhealthy fat) are the biggest culprits when it comes to ...

1 Center for Endocrine Metabolic and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China 2 Beijing Key Laboratory of Diabetes Prevention and Research Care, Beijing Luhe ...

Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults and adolescents aged 12 and older with chronic spontaneous urticaria (CSU) who continue to ...